Hardman & Co Equity Research & Stock Reports
- Professional research and all the latest forecasts, valuation opinions and multiples from Hardman & Co's expert analysts.
- Real-time updates from analysts following company announcements and other events.
- Near-live share prices, user-friendly dashboard, charting and company content.
Low response would be positive!
21 Mar 17
Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to established antibody technology which dominates the drug industry despite its limitations. During 2016, Avacta made considerable progress towards its strategic goal to have a first-in-man Affimer therapeutic by the end of 2019. During coming weeks the company is expected to report on the next step in the pre-clinical development process: whether or not Affimer scaffolds are immunogenic. A positive outcome would be a low immune response rate.
Turbo-charging into a new growth phase
21 Mar 17
Chamberlin is refocussing. Following its major contract win and with improved competitiveness, Chamberlin is further developing its product offering to the automobile turbocharger industry through expansion of its principle operational facilities. The risk/reward profile remains favourable and the shares are attractively valued both against its peer group and on a DCF basis.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
Expanding global distribution network
17 Mar 17
Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down’s syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets is well recognised and the strategic acquisition of Yourgene Bioscience will accelerate this. Meanwhile, Premaitha has moved quickly to expand the availability of IONA throughout Europe and the Middle East, thereby offsetting the impact of financial difficulties being encountered by its largest customer in fiscal 2017.
Delivery of LIGHT
15 Mar 17
AVO is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology originally developed at the world renowned CERN. The company is entering an exciting stage with construction work on its Harley Street site expected to commence this month following preliminary assessment work. Meanwhile, individual modules for the LIGHT system are being integrated and tested in Geneva. At the March 2017 investor presentations, AVO provided a revised timeline for completion of the London Proton Therapy Centre, first patient treatments, and an update on its commercial and financial strategies.
Engineering cartilage repairs
13 Mar 17
Collagen Solutions is a biomaterials company developing and manufacturing medical grade collagen components for use in medical devices, research, and regenerative medicine. A number of investment initiatives have been introduced over the last year to accelerate the rate of growth, including global commercial infrastructure and the development of a pipeline of finished medical devices. ChondroMimetic will be the first of these products and is expected to enhance significantly the value of the company which is not being reflected in the current share price. The recent capital raise and loan facility has resolved funding issues.
Hardman & Co Research and Daily Commentaries
Research Tree offers Hardman & Co research, providing ongoing coverage of 70 shares , as well as macro-economic categories including: Economic Data and Housing Market. We offer 168 reports from Hardman & Co on Research Tree.
Research reports provided by Hardman & Co
Companies covered by Hardman & Co
Sectors covered by Hardman & Co